Top-Rated StocksTop-RatedNASDAQ:NRIX Nurix Therapeutics (NRIX) Stock Forecast, Price & News $11.01 +0.84 (+8.26%) (As of 02:48 PM ET) Add Compare Share Share Today's Range$10.14▼$11.0250-Day Range$8.63▼$13.2852-Week Range$8.34▼$19.91Volume150,622 shsAverage Volume340,786 shsMarket Capitalization$522.31 millionP/E RatioN/ADividend YieldN/APrice Target$29.75 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Nurix Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.91 Rating ScoreUpside/Downside172.0% Upside$29.70 Price TargetShort InterestBearish12.70% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.18Based on 3 Articles This WeekInsider TradingSelling Shares$28,464 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.24) to ($3.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.75 out of 5 starsMedical Sector773rd out of 983 stocksPharmaceutical Preparations Industry388th out of 486 stocks 3.5 Analyst's Opinion Consensus RatingNurix Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $29.70, Nurix Therapeutics has a forecasted upside of 172.0% from its current price of $10.92.Amount of Analyst CoverageNurix Therapeutics has only been the subject of 4 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted12.70% of the float of Nurix Therapeutics has been sold short.Short Interest Ratio / Days to CoverNurix Therapeutics has a short interest ratio ("days to cover") of 14.3, which indicates bearish sentiment.Change versus previous monthShort interest in Nurix Therapeutics has recently increased by 3.08%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldNurix Therapeutics does not currently pay a dividend.Dividend GrowthNurix Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NRIX. Previous Next 2.9 News and Social Media Coverage News SentimentNurix Therapeutics has a news sentiment score of 1.18. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Nurix Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 11 people have searched for NRIX on MarketBeat in the last 30 days. This is a decrease of -48% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Nurix Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Nurix Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,464.00 in company stock.Percentage Held by InsidersOnly 7.20% of the stock of Nurix Therapeutics is held by insiders.Percentage Held by Institutions91.33% of the stock of Nurix Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Nurix Therapeutics are expected to decrease in the coming year, from ($3.24) to ($3.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Nurix Therapeutics is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Nurix Therapeutics is -3.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioNurix Therapeutics has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Nurix Therapeutics (NASDAQ:NRIX) StockNurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.Read More Receive NRIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nurix Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address NRIX Stock News HeadlinesMay 25, 2023 | finance.yahoo.comNurix Therapeutics (NASDAQ:NRIX) shareholders have earned a 25% return over the last yearMay 24, 2023 | finance.yahoo.comDoes Nurix Therapeutics, Inc. (NRIX) Have the Potential to Rally 192.09% as Wall Street Analysts Expect?June 2, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. May 14, 2023 | americanbankingnews.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Given Consensus Rating of "Moderate Buy" by BrokeragesMay 9, 2023 | finance.yahoo.comNurix Therapeutics to Participate in the 2023 RBC Capital Markets Global Healthcare ConferenceMay 4, 2023 | finance.yahoo.comWall Street Analysts Predict a 233.33% Upside in Nurix Therapeutics, Inc. (NRIX): Here's What You Should KnowMay 4, 2023 | finance.yahoo.comWall Street Analysts Predict a 233.33% Upside in Nurix Therapeutics, Inc. (NRIX): Here's What You Should KnowMay 4, 2023 | americanbankingnews.comGwenn Hansen Sells 1,136 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) StockJune 2, 2023 | Edge On The Street (Ad)The Graphite Shortage Story You're Not Being ToldGraphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security. May 3, 2023 | americanbankingnews.comQ2 2023 Earnings Estimate for Nurix Therapeutics, Inc. Issued By HC Wainwright (NASDAQ:NRIX)April 27, 2023 | msn.comHC Wainwright & Co. Reiterates Nurix Therapeutics, Inc. (NRIX) Buy RecommendationApril 24, 2023 | americanbankingnews.comNeedham & Company LLC Reaffirms Buy Rating for Nurix Therapeutics (NASDAQ:NRIX)April 24, 2023 | americanbankingnews.comNurix Therapeutics (NASDAQ:NRIX) Stock Rating Reaffirmed by Needham & Company LLCApril 24, 2023 | americanbankingnews.comNurix Therapeutics (NASDAQ:NRIX) Stock Rating Reaffirmed by Needham & Company LLCApril 21, 2023 | markets.businessinsider.comNeedham Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)April 19, 2023 | finance.yahoo.comNurix Therapeutics, Inc.'s (NASDAQ:NRIX) 30% Price Boost Is Out Of Tune With RevenuesApril 18, 2023 | finance.yahoo.comHow Much Upside is Left in Nurix Therapeutics, Inc. (NRIX)? Wall Street Analysts Think 134.94%April 17, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Cutera (CUTR) and Nurix Therapeutics (NRIX)April 17, 2023 | finance.yahoo.comNurix Therapeutics Presents Data at the American Association for Cancer Research (AACR) Annual Meeting Highlighting Activity of its BTK Targeted Protein Degraders, NX-2127 and NX-5948, against a Broad Range of BTKi Resistance MutationsApril 17, 2023 | markets.businessinsider.comRobert W. Baird Sticks to Their Buy Rating for Nurix Therapeutics (NRIX)April 17, 2023 | americanbankingnews.comNurix Therapeutics, Inc. (NASDAQ:NRIX) Receives Average Recommendation of "Moderate Buy" from AnalystsApril 14, 2023 | msn.comNeedham Reiterates Nurix Therapeutics, Inc. (NRIX) Buy RecommendationApril 14, 2023 | msn.comRBC Capital Reiterates Nurix Therapeutics, Inc. (NRIX) Outperform RecommendationApril 14, 2023 | markets.businessinsider.comNeedham Reaffirms Their Buy Rating on Nurix Therapeutics (NRIX)April 14, 2023 | finanznachrichten.deNurix Therapeutics, Inc.: Nurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate UpdateApril 13, 2023 | finance.yahoo.comNurix Therapeutics Reports First Quarter Fiscal 2023 Financial Results and Provides a Corporate UpdateApril 11, 2023 | finance.yahoo.comNurix Therapeutics to Participate in the 22nd Annual Needham Virtual Healthcare ConferenceSee More Headlines NRIX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRIX Company Calendar Last Earnings10/14/2021Today6/02/2023Next Earnings (Estimated)7/06/2023Fiscal Year End11/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NRIX CUSIPN/A CIK1549595 Webwww.nurixtx.com Phone415-660-5320FaxN/AEmployees242Year FoundedN/APrice Target and Rating Average Stock Price Forecast$29.70 High Stock Price Forecast$53.00 Low Stock Price Forecast$11.00 Forecasted Upside/Downside+192.5%Consensus RatingModerate Buy Rating Score (0-4)2.91 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)($3.53) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-180,360,000.00 Net Margins-428.29% Pretax Margin-428.29% Return on Equity-60.17% Return on Assets-43.54% Debt Debt-to-Equity RatioN/A Current Ratio4.44 Quick Ratio4.44 Sales & Book Value Annual Sales$38.63 million Price / Sales12.49 Cash FlowN/A Price / Cash FlowN/A Book Value$6.44 per share Price / Book1.58Miscellaneous Outstanding Shares47,440,000Free Float44,029,000Market Cap$482.46 million OptionableNot Optionable Beta1.69 Key ExecutivesDr. Arthur T. Sands M.D. (Age 61)Ph.D., CEO, Pres & Director Comp: $842.47kMr. Johannes Van Houte (Age 57)Chief Financial Officer Comp: $606.89kMs. Stefani A. Wolff (Age 60)COO & Exec. VP of Product Devel. Comp: $387.25kDr. Gwenn M. Hansen Ph.D. (Age 52)Chief Scientific Officer Comp: $723.73kDr. Christine Ring (Age 58)Gen. Counsel & Sec. Comp: $595.83kDr. John Kuriyan Ph.D.Founder & Member of Scientific Advisory BoardDr. Michael Rapé Ph.D.Founder & Member of Scientific Advisory BoardProf. Arthur Weiss M.D.Ph.D., Founder & Member of Scientific Advisory BoardMr. Howard A. Simon Esq. (Age 64)J.D., SPHR, VP of Operations & Corp. Counsel Rita KwongSr. Accounting Mang.More ExecutivesKey CompetitorsJanux TherapeuticsNASDAQ:JANXAmarinNASDAQ:AMRNAlpine Immune SciencesNASDAQ:ALPNStoke TherapeuticsNASDAQ:STOKArcutis BiotherapeuticsNASDAQ:ARQTView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 17,949 shares on 5/22/2023Ownership: 0.086%JPMorgan Chase & Co.Sold 53,361 shares on 5/18/2023Ownership: 0.075%New York State Common Retirement FundSold 11,100 shares on 5/18/2023Ownership: 0.042%State Street CorpSold 272,709 shares on 5/16/2023Ownership: 4.711%Geode Capital Management LLCBought 36,475 shares on 5/16/2023Ownership: 1.962%View All Insider TransactionsView All Institutional Transactions NRIX Stock - Frequently Asked Questions Should I buy or sell Nurix Therapeutics stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Nurix Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" NRIX shares. View NRIX analyst ratings or view top-rated stocks. What is Nurix Therapeutics' stock price forecast for 2023? 10 Wall Street research analysts have issued twelve-month price objectives for Nurix Therapeutics' stock. Their NRIX share price forecasts range from $11.00 to $53.00. On average, they anticipate the company's share price to reach $29.70 in the next year. This suggests a possible upside of 192.0% from the stock's current price. View analysts price targets for NRIX or view top-rated stocks among Wall Street analysts. How have NRIX shares performed in 2023? Nurix Therapeutics' stock was trading at $10.98 on January 1st, 2023. Since then, NRIX stock has decreased by 7.4% and is now trading at $10.17. View the best growth stocks for 2023 here. When is Nurix Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, July 6th 2023. View our NRIX earnings forecast. How were Nurix Therapeutics' earnings last quarter? Nurix Therapeutics, Inc. (NASDAQ:NRIX) issued its quarterly earnings data on Thursday, October, 14th. The company reported ($0.65) earnings per share for the quarter, missing analysts' consensus estimates of ($0.63) by $0.02. The company had revenue of $10.25 million for the quarter, compared to analyst estimates of $8.73 million. Nurix Therapeutics had a negative net margin of 428.29% and a negative trailing twelve-month return on equity of 60.17%. What ETFs hold Nurix Therapeutics' stock? ETFs with the largest weight of Nurix Therapeutics (NASDAQ:NRIX) stock in their portfolio include ARK Genomic Revolution ETF (ARKG), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Biotechnology ETF (IBB), Invesco Nasdaq Biotechnology ETF (IBBQ) and ProShares Ultra Nasdaq Biotechnology (BIB). What other stocks do shareholders of Nurix Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Nurix Therapeutics investors own include Datadog (DDOG), Intel (INTC), AbbVie (ABBV), Alibaba Group (BABA), BigCommerce (BIGC), Beyond Meat (BYND), Delta Air Lines (DAL), DocuSign (DOCU), Fastly (FSLY) and Fiverr International (FVRR). When did Nurix Therapeutics IPO? (NRIX) raised $150 million in an initial public offering (IPO) on Friday, July 24th 2020. The company issued 8,800,000 shares at $16.00-$18.00 per share. J.P. Morgan, Piper Sandler and Stifel acted as the underwriters for the IPO and Needham & Company was co-manager. What is Nurix Therapeutics' stock symbol? Nurix Therapeutics trades on the NASDAQ under the ticker symbol "NRIX." Who are Nurix Therapeutics' major shareholders? Nurix Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (9.04%), Wasatch Advisors LP (6.69%), Price T Rowe Associates Inc. MD (5.45%), ARK Investment Management LLC (4.72%), State Street Corp (4.71%) and Pictet Asset Management SA (2.24%). Insiders that own company stock include Christine Ring, Gwenn Hansen, Houte Hans Van, Pierre Beaurang and Stefani Wolff. View institutional ownership trends. How do I buy shares of Nurix Therapeutics? Shares of NRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nurix Therapeutics' stock price today? One share of NRIX stock can currently be purchased for approximately $10.17. How much money does Nurix Therapeutics make? Nurix Therapeutics (NASDAQ:NRIX) has a market capitalization of $482.46 million and generates $38.63 million in revenue each year. The company earns $-180,360,000.00 in net income (profit) each year or ($3.53) on an earnings per share basis. How many employees does Nurix Therapeutics have? The company employs 242 workers across the globe. How can I contact Nurix Therapeutics? The official website for the company is www.nurixtx.com. The company can be reached via phone at 415-660-5320 or via email at wolffe@wheelhouselsa.com. This page (NASDAQ:NRIX) was last updated on 6/2/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nurix Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.